

Nevrargenics reports multi-neuro-restorative and -protective effects suggest DC-645 as a promising new therapeutic strategy for the treatment of ALS

Date

December 2020

Nevrargenics Ltd, the UK biotech company focusing on developing novel small molecule drugs that modulate the retinoic acid receptors to treat neurodegenerative and other diseases, is pleased to announce that it has presented some of its promising results at the British Pharmacological Society conference, Pharmacology 2020.

The results were presented in an abstract with the title “Dual-acting Retinoic Acid Receptor-Modulator DC645, as lead potential drug for developing a rational and effective new treatment regime for ALS”. Nevrargenics’ drug candidate, significantly induced neurite outgrowth and dendritic branching, indicative of neuronal regeneration. Biochemical studies provided evidence that the compound ameliorated neuroinflammation.

In conclusion, the reported multi-neuro-restorative and -protective effects of the drug candidate suggest that it could become a promising new therapeutic strategy for the treatment of ALS.

Notes

ALS, or Amyotrophic Lateral Sclerosis (also referred to as Motor Neurone Disease) is a neurodegenerative disease affecting motoneurons; it is fatal, characterised by progressive muscular atrophy; it is accompanied with cognitive impairment in around half of patients and there are no effective treatments. ALS is an orphan indication.

Retinoic Acid Receptor modulation signalling correlates with axon outgrowth, nerve regeneration and neural maintenance.

For more information, contact:

Prof Andy Whiting, CEO
Nevrargenics Ltd
Ouse House
Mandale Park
Belmont Industrial Estate
Durham DH1 1TT
U.K.

info@nevrargenics.com

www.nevrargenics.com

Nevrargenics Ltd is a UK-based biotech company specialising in the discovery and development of novel medicines for the treatment of neurodegenerative disease, such as Alzheimer's, Parkinson's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and other neurological and psychiatric diseases.